

Manufacturer's Batch Protocol

Product: Equilis Te szuszpenziós injekció lovaknak Batch:A013A01

MEMBER STATE SPECIFIC INFORMATION

Member state:	Hungary
Trade name:	Equilis Te szuszpenziós injekció lovaknak
Marketing authorisation number:	
Target species:	Horse
Total number of containers in this batch:	72 005
Number of containers the release is applied for:	72 005
Volume per container:	1
Number of samples for the competent authority:	-
Date of expiry:	Sep-2016
Name and address of Marketing Authorisation Holder:	Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands, Represented by the local company

16-Mar-2015/as
1103585316/10



Manufacturer's Batch Protocol

Product: Equilis Te szuszpenziós injekció lovaknak Batch:A013A01

SUMMARY INFORMATION ON THE FINAL BATCH OF FINISHED PRODUCT

Common name of product:	Equine tetanus vaccine (inactivated)
Batch number of finished product:	A013A01
Batch number of final bulk:	A013
Pharmaceutical form of finished product:	Suspension for injection
Type of final container:	Hydrolytical class type I glass vial
Date of start of period of validity:	10-Sep-2014
Storage temperature:	2-8 °C
Name and address of manufacturer:	Intervet International B.V. Wim de Körverstraat 35 5831 AN BOXMEER NEDERLAND
Name and address of the batch release site:	Intervet International B.V. Wim de Körverstraat 35 5831 AN BOXMEER NEDERLAND

CERTIFICATION BY THE MANUFACTURER

I herewith certify that concerned batch was manufactured and tested according to the procedures approved by the competent authorities and complies with the quality requirement and that all measures have been taken to demonstrate compliance with Directive 2001/82/EC as amended.

Name:
Function:
Date:
Signature:

S.J.M. Verstegen Qualified Person 20 MAR 2015 
--

Manufacturer's Batch Protocol

Product: Equilis Te szuszpenziós injekció lovaknak Batch:A013A01

FINAL BATCH TESTING (FINISHED PRODUCT)

<u>Date on</u>	<u>Date off</u>	<u>Test results</u>
28-Aug-2014	11-Sep-2014	<u>Sterility (FPC-02)</u> Tested according to Ph. Eur. 0062 / Ph. Eur. 2.6.1. Result: No growth Threshold: No growth Conclusion: Passed
10-Sep-2014	22-Oct-2014	<u>Potency using guinea pigs (FPC-03)</u> Tested according to Ph. Eur. 0697 Result: Conform Threshold: Conform Conclusion: Passed
		<u>Potency Tetanus toxoid (FPC-03)</u> Tested according to Ph. Eur. 0697 Result: 373.78 / 423.28 / 261.11 / 327.15 / 385.77 / 397.40 IU/ml Average: 361 IU/ml Threshold: >= 30 IU/ml Conclusion: Passed
		<u>Identity Toxoid (FPC-03)</u> Tested according to Ph. Eur. 0697 Result: Identity conform Threshold: Identity conform Conclusion: Passed
19-Sep-2014	19-Sep-2014	<u>Determination of pH (FPC-01)</u> Tested according to Ph. Eur. 2.2.3 Result: 7.4 Threshold: 6.0 – 8.0 Conclusion: Passed
07-Oct-2014	07-Oct-2014	<u>Identity (Iscom-matrix adjuvant) (FPC-06)</u> Result: Iscoms present Threshold: Presence of iscoms Conclusion: Passed

Manufacturer's Batch Protocol

Product: Equilis Te szuszpenziós injekció lovaknak Batch:A013A01

FINAL BATCH TESTING (FINISHED PRODUCT)

<u>Date on</u>	<u>Date off</u>	<u>Test results</u>
12-Sep-2014	12-Sep-2014	<u>Saponin fraction C</u> Result: 479 µg/ml Threshold: 250 – 500 µg/ml Conclusion: Passed
25-Aug-2014	25-Aug-2014	<u>Appearance (FPC-05)</u> Result: Conform Threshold: Clear opalescent fluid Conclusion: Passed

Manufacturer's Batch Protocol

Product: Equilis Te szuszpenziós injekció lovaknak Batch:A013A01

PRODUCTION INFORMATION

<u>Component</u>	<u>Batch</u>	<u>Site(s) of manufacturing</u>
Tetanus toxoid	See composition table	Novartis/Chiron, Marburg, Germany
Bulk vaccin	See blending	Intervet, Boxmeer, the Netherlands
Filled product	See filling	Intervet, Boxmeer, the Netherlands

STARTING MATERIALS:

Virus seed lots:

Master seed material: **Tetanus toxoid**
MS-batch number: **E21**
Date of last testing: **18-JAN-1973**

Working seed material: **Tetanus toxoid**
WS-batch number: **E122**
Date of last testing: **25-Jan-2012**

INTERMEDIATE STAGES OF PRODUCTION

PRODUCTION OF TETANUS TOXOID:

<u>Production step</u>	<u>Start</u>	<u>End</u>	<u>Volume</u>
Batch 0000305576			
Seed:	10-Jul-2013	04-Oct-2013	- mL
Harvest:	17-Jul-2013	10-Oct-2013	6600 kg
Inactivation:	17-Jul-2013	10-Oct-2013	250 kg
Purification:	18-Dec-2013	20-Dec-2013	17.2 kg

CREATION OF THE FINISHED PRODUCT

BLENDED OF FINAL BULK:

Batch number: **A013**
Start date: **14-Aug-2014**
End date: **14-Aug-2014**
Total volume: **90.0 kg**

COMPOSITION OF THE FINAL BULK

<u>Component</u>	<u>Batch number</u>	<u>Total units</u>
Tetanus toxoid	0000305576	847 g
Iscom matrix adjuvant	0000269777	1419 g*
	0000269779	2157 g**
Buffer	0000229076	To 85.53 kg
	0000291116	
	0000186136	
	BMGM406821	

* containing 13.5 g Saponine fraction C

** containing 20.2 g Saponine fraction C

Manufacturer's Batch Protocol

Product: Equilis Te szuszpenziós injekció lovaknak Batch:A013A01

FILLING

Batch number of final bulk: **A013**
Final batch number: **A013A**
Start date: **18-Aug-2014**
End date: **18-Aug-2014**
Filled containers: **72 005**
Volume filled: **1 ml**

IN PROCESS CONTROLS

In process controls Tetanus toxoid:

<u>Test</u>	<u>Start</u>	<u>End</u>	<u>Result</u>	<u>Thresholds</u>	<u>Conclusion</u>
Batch 0000305576					
Sterility (122/1)	09-Jan-2014	23-Jan-2014	No growth	No growth	Passed
pH value (122/2)	23-Dec-2013	23-Dec-2013	7.3	7.0 – 7.8	Passed
Sulphate determination (122/3)	13-Jan-2014	13-Jan-2014	2 mg/l	≤ 200 mg/l	Passed
Formaldehyde determ. (122/4)	08-Jan-2014	08-Jan-2014	14 mg/l	≤ 200 mg/l	Passed
Sodium Chloride determ. (122/5)	08-Jan-2014	08-Jan-2014	8 mg/ml	8 - 9 mg/ml	Passed
LF content (122/6)	02-Jan-2014	02-Jan-2014	4250 Lf/ml	≥ 2500 Lf/ml	Passed
Nitrogen determination (122/7)	02-Jan-2014	02-Jan-2014	2.568 mg/ml	n.a.	Passed
Purity (122/8)	02-Jan-2014	02-Jan-2014	1655 Lf/mg	≥ 1000 Lf/mg	Passed
Specific toxicity/ Irreversibility of Toxoiding (122/9-10)	02-Jan-2014	13-Feb-2014	*	*	Passed

* No animal shows signs or dies from tetanus, at least 80% surviving animals

In process controls final product:

<u>Test</u>	<u>Start</u>	<u>End</u>	<u>Result</u>	<u>Thresholds</u>	<u>Conclusion</u>
Filling volume (IPC-05)	18-Aug-2014	18-Aug-2014	1.17 ml	1.08-1.32 ml	Passed

**Model for manufacturers of a
MARKETING INFORMATION FORM**


Notification of the intention to market a batch of an immunological veterinary medicinal product, which has a marketing authorisation in the following EC/EEA Member State Hungary and has received an EC Batch release certificate after OBPR or OCABR in another Member State in accordance with Article 81 or Article 82 of EC Directive 2004/28/EC and in view of mutual recognition.

Trade name in the above mentioned Member State:	Equilis Te szuszpenziós injekció lovaknak
International non-proprietary name / Ph. Eur. name / common name:	Equine tetanus vaccine (inactivated)
Name and address of Marketing Authorisation Holder (MAH) for the above mentioned Member State:	Intervet International B.V. Wim de Körverstraat 35 5831 AN Boxmeer Represented by the local company
Market authorisation number in the above mentioned Member State:	EU/2/05/055/001-002
Identification numbers associated with the lot to be marketed in the above mentioned Member State;	
Bulk number (final formulated bulk):	A013
Final lot number:	A013A
Packaging lot number (if different from final lot n°):	A013A01
Batch number of diluent: (where appropriate)	-
Type of Container:	Hydrolytical class type I glass vial
Number of doses/volume of container:	1
Total number of containers to be marketed in the above noted Member State:	2 390
Proposed date of marketing:	After approval batch release
Assigned expiry date for this lot in the above noted Member State:	Sep-2016

CA/OMCL performing batch release:	PEI
Type of certificate: (i.e.: OCABR or OBPR)	OBPR
Official batch release certificate number:	8328/14

I hereby declare that:

- this batch is in compliance with the above marketing authorisation and the relevant European Pharmacopoeia monographs;
- this batch is the batch referred to in the accompanying batch release certificate;
- a copy of the batch release certificate (in the case of OCABR with the annexed test results) and the manufacturer's protocol are attached.

Signature of qualified person (MAH):	 S.J.M. Verstegen Qualified Person 20 MAR 2015
Name of qualified person (MAH):	
Date of issue:	

----- Use of the following section is optional -----

For completion by the CA/OMCL after submission:

Date received:	
Signature of qualified authority (CA/OMCL):	
Name of qualified authority (CA/OMCL):	
Decision and Date:	

20-Mar-2015/sl

Paul-Ehrlich-Institut Postfach D-63207 Langen

Intervet International B.V.
Wim de Körverstraat 35
NL - 5830 AA Boxmeer

Reference Number: 8328/14
Administrative Code: 4/1:2.04.01.0026
Date of Release of Certificate: 08.12.2014

**EU/EEA OFFICIAL BATCH PROTOCOL REVIEW
CERTIFICATE OF APPROVAL
FOR IMMUNOLOGICAL VETERINARY MEDICINAL PRODUCTS**

Examined under Article 81 of Directive 2001/82/EC as amended by Directive 2004/28/EC

Trade name:	Equilis Te
International non-proprietary name / Ph. Eur. name / common name:	-
Name and address of manufacturer responsible for batch release:	Intervet International B.V. Wim de Körverstraat 35 NL - 5830 AA Boxmeer
Marketing authorisation number (Member State / EC):	EU/2/05/055/001
Manufacturer's batch number(s): - final bulk no - final lot no - packaging lot no	A013 A013A A013A01-10
Batch number of diluent (where appropriate):	-
Type of container:	glass vial
Total number of containers of this batch:	72,005
Number of doses/volume per container:	1
Date of start of period of validity:	10.09.2014
Expiry date:	08.2016

This batch has been examined using documented procedures that form part of a quality management system.

The signed manufacturer's release protocol for this batch has been examined in conformity with Article 81.

This batch is in compliance with all of the approved specifications laid down in the above noted marketing authorisation.

Fees are laid down separately.


Dr. Birgit Kegel

